CompletedPHASE1, PHASE2NCT00481871
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Studying Lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Acrotech Biopharma Inc.
- Principal Investigator
- Michael Saunders, MDSpectrum Pharmaceuticals, Inc
- Intervention
- Pralatrexate Injection(drug)
- Enrollment
- 119 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2011
Study locations (15)
- University of California at Los Angeles, Los Angeles, California, United States
- Stanford University School of Medicine, Stanford, California, United States
- Rocky Mountain Cancer Center, Denver, Colorado, United States
- University of Chicago Hospital, Chicago, Illinois, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- University of Nebraska Medical Center, Omaha, Nebraska, United States
- The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
- New York University Hospital, New York, New York, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- UT MD Anderson Cancer Center, Houston, Texas, United States
- Cancer Therapy & Research Center, San Antonio, Texas, United States
- Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00481871 on ClinicalTrials.govOther trials for Lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07372352Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCLThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE1NCT07198087A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy ParticipantsOno Pharmaceutical Co. Ltd
- RECRUITINGNANCT07191431A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）Ruijin Hospital
- RECRUITINGPHASE1, PHASE2NCT07018752A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell LymphomasThe Lymphoma Academic Research Organisation
- RECRUITINGNANCT07058064WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)Mayo Clinic
- RECRUITINGPHASE1NCT06699771Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell MalignanciesGC Cell Corporation
- RECRUITINGPHASE2NCT06530550PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGNANCT06296368DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology ClinicsUNC Lineberger Comprehensive Cancer Center